What Are the Side Effects of Melatonin in the Elderly?

If you're 65 or older and struggling with sleep, you've probably heard about melatonin. It sounds simple: a natural hormone, available without a prescription, and safer than prescription sleeping pills. But "natural" doesn't mean "without risks"—especially for aging bodies that metabolize supplements differently.

The truth is reassuring overall: melatonin is generally well tolerated in seniors. But age-related changes in how your body processes medications mean that risks that might be minor in younger people can become significant concerns for you. And if you're taking other medications—which most seniors are—the risks multiply.

This guide walks through every side effect you should know about, why elderly people experience them differently, how your medications might amplify the problem, and what dosing strategies minimize risk.

Table of Contents

1. Melatonin's Overall Safety Profile in Seniors
2. Common Side Effects—And How Often They Actually Occur
3. Why Elderly Bodies Handle Melatonin Differently
4. Blood Pressure and Cardiovascular Effects
5. The Polypharmacy Problem: When Other Medications Multiply Risk
6. Falls, Fractures, and Injury Risk
7. Safe Dosing for Elderly Patients
8. When Elderly People Should Avoid Melatonin Entirely
9. Getting the Right Formulation Matters
10. Elderly-Specific Questions Answered

1. Melatonin's Overall Safety Profile in Seniors

Let's start with the reassurance: melatonin is significantly safer than prescription alternatives. Benzodiazepines (like diazepam) and Z-drugs (like zolpidem) carry well-documented risks of cognitive decline, dependence, and falls in elderly patients. Melatonin doesn't cause any of those problems.

In clinical trials conducted specifically in adults 55–93 years old, adverse effects from melatonin (2 mg prolonged-release) ranged from 6–24%, compared with 5–21% in placebo groups. The difference is often not statistically significant—many side effects reported were mild and resolved quickly. No studies report serious adverse events or hospitalizations attributable to melatonin alone in elderly patients.

That said, "generally safe" is different from "risk-free for you." Age-related changes in kidney and liver function, the prevalence of multiple medications in seniors, and age-specific physiological shifts create conditions where melatonin poses particular concerns that younger people don't face.

2. Common Side Effects—And How Often They Actually Occur

The most frequently reported side effects in elderly melatonin users are mild and temporary. Here's what the research actually shows:

Daytime drowsiness (5–10% of users): This is the leading complaint, especially if you take melatonin too late at night or at too high a dose. In younger adults, melatonin clears the bloodstream in 1–2 hours. But in elderly people, clearance is often slower, meaning residual melatonin lingers into morning hours. If you wake up groggy, the dose is too high or the timing is wrong.

Dizziness or lightheadedness (3–5%): Melatonin reduces blood pressure in many people. For someone already taking antihypertensive medication, this additive effect can cause orthostatic hypotension—the sudden dizziness you feel when standing up. This becomes a fall risk.

Headache (5–8%): Melatonin affects cerebral blood vessel tone and can trigger headaches in sensitive individuals. This is generally mild and dose-dependent—reducing your dose often solves it.

Nausea or stomach discomfort (3–5%): Some seniors experience GI irritation, particularly if taking melatonin on an empty stomach. Taking it with a small snack usually resolves this.

Vivid dreams or nightmares (2–5%): Melatonin increases REM sleep, the stage where most dreaming occurs. More time in REM means more dreams—and for some people, more intense or disturbing ones. This typically diminishes as your body adjusts.

3. Why Elderly Bodies Handle Melatonin Differently

Your body's chemistry changes with age. Understanding how melatonin metabolism shifts is key to understanding why dosing matters so much in seniors.

Peak blood levels are higher in elderly patients: Melatonin is metabolized primarily by a liver enzyme called CYP1A2 (with minor contributions from CYP2C19). As you age, these enzyme systems become less efficient. A 2 mg dose in a 70-year-old reaches higher peak concentrations than the same dose in a 40-year-old. This is why the same dose causes side effects in elderly patients but not in younger adults.

Elimination half-life may be slower: Melatonin normally clears the bloodstream in 1–2 hours. But variability increases with age, and certain medications slow this further. If you're taking an SSRI antidepressant, the clearance can extend substantially, meaning melatonin accumulates.

Bioavailability is unpredictable (1–74%): How much of an oral melatonin dose actually enters your bloodstream varies widely, even in younger people. In elderly patients with altered gastric pH, reduced GI motility, or certain medications, this variability increases further. This is why two seniors taking the same brand and dose can experience very different effects.

Liver and kidney function decline: If you have even mild hepatic impairment (liver disease, reduced liver perfusion) or renal impairment (reduced kidney function), melatonin and its metabolites accumulate. Seniors with diabetes, cardiovascular disease, or a history of liver problems need extra caution.

4. Blood Pressure and Cardiovascular Effects

One of melatonin's most reliable effects in human studies is blood pressure reduction. For some elderly patients with uncontrolled hypertension, this is a benefit. For others—especially those on blood pressure medications—it becomes a risk.

How much does melatonin lower blood pressure? In clinical trials, repeated melatonin intake (2.5 mg daily) reduced systolic and diastolic blood pressure during sleep by approximately 6 and 4 mmHg, respectively. This reduction is comparable to some antihypertensive medications and happens most reliably in the early morning (3:00–8:00 AM)—precisely when cardiovascular events become more common in elderly people.

The concern: If you're already taking a blood pressure medication, adding melatonin can push your blood pressure too low. Chronically low blood pressure (hypotension) in elderly patients increases dizziness, fainting, falls, and acute coronary events. Some elderly patients report feeling faint or dizzy after starting melatonin, which is often a blood pressure effect.

Special case—nifedipine interaction: One study found that melatonin actually *increased* blood pressure when taken with the calcium channel blocker nifedipine. This highlights that melatonin's cardiovascular effects are unpredictable and drug-dependent.

What to do: If you take blood pressure medication and want to try melatonin, have your doctor monitor your blood pressure (ideally 24-hour ambulatory monitoring) before and during use. Watch for dizziness or unusual fatigue. Consider lower doses (0.3–0.5 mg) and discuss whether reducing your blood pressure medication might be appropriate.

5. The Polypharmacy Problem: When Other Medications Multiply Risk

The average senior takes 5+ prescription medications. This is where melatonin becomes truly risky—not from the melatonin itself, but from interactions.

Antidepressant interactions are the biggest concern: Melatonin is metabolized by the liver enzyme CYP1A2. Certain antidepressants—particularly fluvoxamine (Luvox)—powerfully inhibit this enzyme. When fluvoxamine blocks CYP1A2, melatonin blood levels can increase 12-fold or more. This causes excessive drowsiness, prolonged sedation, and increased fall risk.

Other SSRIs like citalopram (Celexa) or fluoxetine (Prozac) can also raise melatonin levels, though the effect is usually smaller. If you also take a proton pump inhibitor (like omeprazole for acid reflux), the interaction worsens because PPIs inhibit CYP2C19, a secondary melatonin-metabolizing enzyme.

What to do if you take antidepressants: Tell your doctor before starting melatonin. If you're on fluvoxamine, melatonin may not be safe at all. If you're on other SSRIs, your doctor can watch for excessive daytime drowsiness and adjust your dose accordingly. Lower doses (0.3–1 mg) are safer when taken with antidepressants.

Other medication interactions: Melatonin may interact with blood thinners (warfarin), diabetes medications (by affecting insulin sensitivity), immunosuppressants, and seizure medications. It's not that melatonin causes severe problems—it's that the interaction creates *uncertainty* about how much melatonin will actually be in your bloodstream.

The core issue with polypharmacy: In the U.S., melatonin is unregulated as a dietary supplement, so the amount of melatonin in a bottle can vary wildly (sometimes ±50% from the label). Combined with age-related absorption variability and drug interactions, a 2 mg dose could effectively become 0.5 mg or 5 mg depending on your medications and how your body processes it. This unpredictability is what makes polypharmacy seniors highest risk.

6. Falls, Fractures, and Injury Risk

The relationship between melatonin and falls in elderly people is complicated—and often overstated online.

What the data actually shows: In a large UK study, elderly patients taking melatonin (45+ years old) showed a modest increased fracture risk, but only when they had taken 3+ melatonin prescriptions (suggesting chronic use). The effect size was small compared to benzodiazepines and Z-drugs, which showed much stronger associations with falls and fractures. Importantly, melatonin was not significantly associated with fractures in other studies, suggesting the relationship may be indirect (through daytime drowsiness or dizziness) rather than a direct drug effect.

The realistic concern: Daytime drowsiness (5–10% of users) and dizziness (3–5%) are real. In an elderly person with balance problems, weak leg muscles, or vision impairment, even mild drowsiness becomes a fall risk. And falls in people over 75 often result in hip fractures, which can trigger a cascade of disability and mortality.

Risk factors that increase fall danger: You face higher fall risk if you (1) already have a history of falls, (2) take other CNS-depressing drugs (sedatives, opioids), (3) have orthostatic hypotension (blood pressure drops when standing), (4) have neuropathy or balance disorders, or (5) live alone without assistance.

What to do: If fall risk is already a concern, melatonin is worth discussing with your doctor. If you try it, start with the lowest possible dose (0.3–0.5 mg), take it earlier in the evening (8–9 PM rather than right before bed), and have someone monitor you the first few nights. Watch for stumbling, unsteadiness, or grogginess in the morning.

7. Safe Dosing for Elderly Patients

Dosing is where the biggest difference between elderly and younger people shows up. The recommendation is simple: use far less than you probably think.

Recommended dose for seniors: 0.3–2 mg, taken 1 hour before bedtime.

Most large clinical trials in elderly patients used 2 mg (prolonged-release formulation). This dose showed modest benefits for sleep onset (reducing sleep latency by 8–15 minutes) and was well tolerated. Some gerontologists now recommend even lower doses (0.3–0.5 mg) as a starting point, because many side effects don't appear until doses exceed 2 mg in elderly populations.

Why not 5–10 mg? Those doses are commonly available over-the-counter and popular with younger people. But research in elderly patients specifically shows that doses above 2 mg provide little additional sleep benefit and increase side effect risk significantly. Exposure to higher melatonin concentrations can lead to melatonin receptor desensitization—your body's receptors become less responsive—potentially worsening insomnia over time if you keep escalating the dose.

Formulation matters: Immediate-release melatonin (regular tablets/liquid) peaks quickly and clears faster, causing less next-day grogginess. Prolonged-release formulations maintain melatonin levels longer, which is good for staying asleep but bad for morning alertness. Elderly people often tolerate immediate-release better, though prolonged-release works well if taken early enough (8–9 PM).

How long to take it: Melatonin is not intended for long-term daily use in seniors. Clinical trials used durations of 2–12 weeks. Long-term use (months or years) lacks safety data in elderly patients. If you're still not sleeping better after 2–4 weeks, melatonin probably isn't working for you—continuing it exposes you to ongoing interaction risks without benefit.

8. When Elderly People Should Avoid Melatonin Entirely

Melatonin is not appropriate for everyone. Skip it if you have:

Uncontrolled hypertension: If your blood pressure is already high or unstable, melatonin's blood pressure-lowering effect could destabilize it further.

History of bleeding or on blood thinners: Some research suggests melatonin may have mild anticoagulant effects. If you're on warfarin or similar medications, the interaction risk is too high.

Severe liver disease: Your liver is where melatonin is metabolized. If you have cirrhosis, hepatitis, or significantly impaired liver function, melatonin accumulates to dangerous levels.

Seizure disorder: Melatonin's effects on seizure threshold are unpredictable. Some research suggests it may lower the seizure threshold; other research suggests the opposite. Don't experiment without explicit approval from your neurologist.

Autoimmune disease: Melatonin is a potent immune modulator. If you have rheumatoid arthritis, lupus, or other autoimmune conditions, melatonin can trigger flares or interfere with treatment.

Taking fluvoxamine (Luvox): The interaction is simply too strong. Your doctor will advise against it or use a different antidepressant.

Already on multiple CNS depressants: If you're taking sedatives, opioids, or other sleep aids, adding melatonin increases overdose risk and fall risk too much.

9. Getting the Right Formulation Matters

One reason melatonin's side effects vary so widely in elderly patients is inconsistent product quality. Melatonin is a dietary supplement in the U.S., meaning the FDA doesn't regulate potency, purity, or labeling. Some bottles contain 30% less melatonin than labeled; others contain 30% more. Some contain contaminating serotonin (which can cause its own complications, especially with antidepressants).

For elderly patients, this unpredictability is dangerous. You need to know exactly how much melatonin you're getting so you can predict side effects and manage interactions.

What to look for: Choose melatonin supplements verified by a third-party testing organization like USP (U.S. Pharmacopeia), ConsumerLab, or NSF. The verification mark on the label confirms the supplement contains what it says it contains, at the right potency.

BioAbsorb Melatonin is third-party tested and USP-verified, with transparent labeling of melatonin content. Available in multiple formulations—immediate-release (faster onset, less next-day grogginess) and extended-release (better for sleep maintenance)—each dosed for elderly safety (0.5–2 mg). If you choose a liposomal formulation, improved absorption means slightly higher bioavailability, which is beneficial when you need predictable dosing but requires starting at the lower end of the dose range (0.3–0.5 mg instead of 1–2 mg).

10. Elderly-Specific Questions Answered

Q: Is melatonin safer than Ambien (zolpidem) for me as a senior?
A: Yes, substantially. Ambien carries risks of cognitive decline, morning grogginess that increases fall risk, and dependence—none of which apply to melatonin. However, melatonin is also less effective; expect a 10–15 minute reduction in time to fall asleep with melatonin, versus 30–45 minutes with Ambien. Start with melatonin because it's safer. If it doesn't work after 2–4 weeks at appropriate doses, discuss prescription alternatives with your doctor.

Q: I'm 78 and on blood pressure medication. Can I take melatonin?
A: Possibly, but with caution and monitoring. Melatonin lowers blood pressure modestly. If you're already well-controlled on medication, adding melatonin could push you too low. Have your doctor check your 24-hour ambulatory blood pressure before and after starting melatonin. Start with 0.3 mg and watch for dizziness.

Q: I take sertraline (Zoloft). Can I take melatonin?
A: Yes, but at a lower dose. Sertraline is less of a CYP1A2 inhibitor than fluvoxamine, so the interaction is moderate rather than severe. Talk to your doctor about starting at 0.3–0.5 mg instead of 1–2 mg. If you experience excessive drowsiness, reduce the dose further.

Q: I've been taking 10 mg melatonin for three years. Is that safe?
A: Probably not long-term, especially as a senior. That dose is too high for elderly patients—your body may have developed partial tolerance (receptor desensitization), meaning the dose becomes less effective over time. More concerning, 3 years of use exceeds the safety data window. Discuss tapering down with your doctor and consider whether sleep problems have underlying causes (sleep apnea, medication side effects, untreated depression) that should be addressed instead.

Q: What if melatonin makes me too drowsy in the morning?
A: Take it earlier in the evening (8–9 PM instead of 10–11 PM) or switch to immediate-release instead of prolonged-release. Both allow melatonin to clear your system before morning. If drowsiness persists, lower the dose by half and see if that helps.

Conclusion

Melatonin is generally safe for seniors and significantly safer than prescription sleep aids. But aging bodies process supplements differently, and most elderly people take multiple medications that interact with melatonin in unpredictable ways. The key is starting low (0.3–2 mg), choosing a third-party tested product so you know what you're taking, and monitoring closely for blood pressure and dizziness changes. If you have concerns about any of the side effects described here, or if you're on multiple medications, discuss melatonin with your doctor before starting.

Consult your doctor before taking melatonin, especially if you're over 75, take blood pressure medications, take antidepressants, or have a history of falls or low blood pressure.

Research References

1. Benefits and adverse events of melatonin use in the elderly. PubMed Central (2023). Comprehensive review of melatonin pharmacology and safety in older adults, documenting common side effects (headache, nausea, dizziness) and age-specific cardiovascular effects (blood pressure reduction, hypothermia risk).
2. Should Melatonin Be Used as a Sleeping Aid for Elderly People? Canadian Medical Association Journal (2019). Clinical evidence that experts recommend low doses (0.3–2 mg) for elderly patients; demonstrates that maximum concentrations are higher in older versus younger adults, requiring dose adjustment to avoid side effects.
3. Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults. Clinical Interventions in Aging (2023). Narrative systematic review identifying multiple factors that increase adverse effect risk in elderly patients, including polypharmacy, hepatic impairment, and CYP1A2/CYP2C19 enzyme inhibition via concurrent medications.
4. Melatonin to Treat Insomnia in Older Adults. American Family Physician, Vol. 104(3) (2021). Meta-analysis of RCTs in elderly patients (55–93 years); shows adverse effect rates of 6–24% with melatonin versus 5–21% with placebo, indicating marginal absolute risk difference in clinical practice.
5. Optimal Dosages for Melatonin Supplementation Therapy in Older Adults: A Systematic Review of Current Literature. Drugs & Aging, Vol. 31(9) (2014). Systematic review of 9 RCTs and 5 case-control studies demonstrating that melatonin bioavailability is highly variable (1–74%) and dose-dependent in adults 55+, with higher peak concentrations in elderly versus younger populations.
6. Should Lower Doses of Melatonin Be Used For Older Adults? American Journal of Managed Care (2024). Evidence that exposure to supra-physiological melatonin concentrations causes receptor desensitization; doses >6 mg offer little additional benefit and increase side effect risk in elderly patients.
7. Cytochrome P450 Isoforms Involved in Melatonin Metabolism in Human Liver Microsomes. Journal of Pineal Research, Vol. 26(3) (1999). Foundational pharmacokinetics study identifying CYP1A2 as primary melatonin metabolizing enzyme and documenting potent inhibition by fluvoxamine, explaining basis for dangerous SSRI-melatonin interactions.
8. Sedative-Hypnotic Drug Use and Risk of Falls and Fractures in Elderly Patients: A Cross-Sectional Study. BMC Geriatrics (2024). Large cross-sectional study (200 elderly patients ≥60 years) showing melatonin use was not statistically associated with fractures, unlike benzodiazepines; however, polypharmacy with fall-risk medications does increase fracture risk.
9. Polypharmacy and Falls in the Elderly: A Literature Review. PubMed Central (2013). Systematic literature review demonstrating that polypharmacy-associated fall risk is driven primarily by medication *type* (CNS-depressing drugs) rather than number of drugs, and that fall risk increases significantly when elderly patients take medications known to cause falls.
10. Daily Nighttime Melatonin Reduces Blood Pressure in Male Patients With Essential Hypertension. Hypertension, Vol. 43 (2004). Double-blind, placebo-controlled RCT demonstrating that repeated melatonin intake (2.5 mg) reduces systolic and diastolic blood pressure during sleep by 6 and 4 mmHg, respectively, with effects most pronounced in early morning hours (period of highest cardiovascular risk).
11. The Effect of CYP2C19 Substrate on the Metabolism of Melatonin in the Elderly: A Randomized Double-Blind Placebo-Controlled Study. Journal of Pineal Research (2006). RCT in elderly psychogeriatric patients showing that CYP2C19 substrate drugs (citalopram, omeprazole) increase melatonin metabolite excretion 156-fold versus 72-fold in melatonin-only group; metabolite remained elevated 6 days post-treatment, indicating prolonged plasma melatonin accumulation.
12. Melatonin, hypnotics and their association with fracture: a matched cohort study. Age and Ageing, Vol. 45(6) (2016). Large cohort study in UK primary care (45+ years) showing elevated fracture risk only in patients with 3+ melatonin prescriptions; effect size smaller than benzodiazepines, suggesting indirect mechanism (daytime drowsiness/dizziness) rather than direct pharmacological effect.

About the Author

BioAbsorb Editorial Team — Evidence-Based Supplement Guidance
Our team includes researchers, registered dietitian nutritionists, and clinical advisors who synthesize peer-reviewed research into practical, honest guidance for supplement safety and efficacy. We focus on populations with unique needs—aging adults, people with chronic disease, those on complex medication regimens—where supplement safety is highest priority. Every article cites the original research and acknowledges limitations in the evidence base.

Medical Disclaimer

Important: This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Do not use this information to self-diagnose a medical condition or start any new supplement without consulting a healthcare provider. Melatonin supplements, while available over-the-counter, are not appropriate for everyone and may interact with your medications or medical conditions in ways that could be harmful. Always tell your doctor about any supplements you take, including melatonin. If you experience side effects or symptoms of concern, contact your healthcare provider immediately. BioAbsorb does not provide medical advice, and nothing in this article should be interpreted as medical advice. The information presented reflects current research but is not a guarantee of outcomes. Individual responses to supplements vary based on genetics, age, medications, health status, and many other factors beyond our control or knowledge. Your doctor is your best source of personalized medical guidance.

FDA/Health Canada Disclaimer

Melatonin Regulatory Status: Melatonin is classified as a dietary supplement in the United States and Canada, meaning it is not reviewed by the FDA or Health Canada for safety or efficacy before marketing. The FDA does not regulate dietary supplements with the same rigor applied to prescription medications. Melatonin manufacturers are responsible for ensuring that products are safe and that label claims are truthful and not misleading, but pre-market approval is not required. This article does not constitute an endorsement of any melatonin product or brand, including BioAbsorb. Statements about melatonin's effects are based on clinical research but have not been evaluated by the FDA or Health Canada. Melatonin is not intended to diagnose, treat, cure, or prevent any disease. If you are pregnant, nursing, have a medical condition, or take medications, consult your healthcare provider before using melatonin supplements. Be aware that the actual melatonin content in dietary supplement products can vary significantly from the label amount. Choose products verified by third-party testing (USP, ConsumerLab, NSF) to increase confidence in product quality and accuracy of labeling.